PMID- 23634290
OWN - NLM
STAT- MEDLINE
DCOM- 20140207
LR  - 20211021
IS  - 2045-7634 (Print)
IS  - 2045-7634 (Electronic)
IS  - 2045-7634 (Linking)
VI  - 2
IP  - 2
DP  - 2013 Apr
TI  - Discordance in HER2 gene amplification in circulating and disseminated tumor 
      cells in patients with operable breast cancer.
PG  - 226-33
LID - 10.1002/cam4.70 [doi]
AB  - Human epidermal growth factor receptor 2 (HER2) gene amplification in circulating 
      tumor cells (CTCs) and disseminated tumor cells (DTCs) might be useful for 
      modifying Herceptin therapy in breast cancer. In the process of investigating the 
      utility of a microfluidic platform for detecting HER2 gene amplification in these 
      cells, we observed novel results on discordance of HER2 status. Peripheral blood 
      (8.5 mL) and bone marrow (BM) (7.5-10 mL) were collected prospectively from 
      patients with clinical stages I-IV breast cancer. Mononuclear cells were 
      recovered, stained with cytokeratin (CK), CD45, and DAPI, and processed through 
      microfluidic channels for fluorescence in situ hybridization (FISH). A ratio of 
      HER2:CEP17 >2 in any CK+/CD45 or CK-/CD45 cell was regarded as positive for HER2 
      gene amplification. Peripheral blood from 95 patients and BM from 78 patients 
      were studied. We found CK+/CD45-/DAPI+ CTCs in 27.3% of patients. We evaluated 
      HER2 gene amplification by FISH in 88 blood and 78 BM specimens and found HER2+ 
      CTCs in 1 of 9 (11.1%) and HER2+ DTCs (27.2%) in 3 of 11 patients with HER2+ 
      primary tumor. Among patients with a HER2- primary tumor, 5 of 79 had HER2+ CTCs 
      (6.3%) and 14 of 67 had HER2+ DTCs (20.8%). The overall rate of discordance in 
      HER2 status was 15% between primary tumor and CTCs and 28.2% between primary 
      tumor and DTCs. HER2 was amplified in CTCs and DTCs in a portion of both HER2+ 
      and HER2- primary tumors. HER2 discordance was more frequent for DTCs. The 
      clinical implications of evaluating HER2 status in CTCs and DTCs in breast cancer 
      needs to be established in prospective clinical trials. The cell enrichment and 
      extraction microfluidic technology provides a sensitive platform for evaluation 
      of HER2 gene amplification in CTCs and DTCs.
FAU - Krishnamurthy, Savitri
AU  - Krishnamurthy S
AD  - Department of Pathology, The University of Texas MD Anderson Cancer Center 
      Houston, Texas 77030, USA. skrishna@mdanderson.org
FAU - Bischoff, Farideh
AU  - Bischoff F
FAU - Ann Mayer, Julie
AU  - Ann Mayer J
FAU - Wong, Karina
AU  - Wong K
FAU - Pham, Tam
AU  - Pham T
FAU - Kuerer, Henry
AU  - Kuerer H
FAU - Lodhi, Ashutosh
AU  - Lodhi A
FAU - Bhattacharyya, Anirban
AU  - Bhattacharyya A
FAU - Hall, Carolyn
AU  - Hall C
FAU - Lucci, Anthony
AU  - Lucci A
LA  - eng
GR  - DAMD 17-03-01-0669/PHS HHS/United States
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
DEP - 20130306
PL  - United States
TA  - Cancer Med
JT  - Cancer medicine
JID - 101595310
RN  - 0 (Biomarkers, Tumor)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Biomarkers, Tumor/genetics
MH  - Breast Neoplasms/*genetics/surgery
MH  - Female
MH  - *Gene Amplification
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplastic Cells, Circulating/*metabolism
MH  - Receptor, ErbB-2/*genetics
MH  - Tumor Cells, Cultured
PMC - PMC3639661
OTO - NOTNLM
OT  - Breast cancer
OT  - HER2 status
OT  - circulating tumor cells
OT  - disseminated tumor cells
OT  - minimal residual disease
EDAT- 2013/05/02 06:00
MHDA- 2013/05/02 06:01
PMCR- 2013/04/01
CRDT- 2013/05/02 06:00
PHST- 2012/07/15 00:00 [received]
PHST- 2013/01/25 00:00 [revised]
PHST- 2013/01/28 00:00 [accepted]
PHST- 2013/05/02 06:00 [entrez]
PHST- 2013/05/02 06:00 [pubmed]
PHST- 2013/05/02 06:01 [medline]
PHST- 2013/04/01 00:00 [pmc-release]
AID - 10.1002/cam4.70 [doi]
PST - ppublish
SO  - Cancer Med. 2013 Apr;2(2):226-33. doi: 10.1002/cam4.70. Epub 2013 Mar 6.